Board of Directors

CRH Medical Board of Directors

Composed of accomplished physicians and business leaders, our board of directors is focused on building a company with exceptional medical impact – and ongoing financial success.

 

Dr. Anthony F. Holler

Dr. Anthony F. Holler - Chairman of the Board

Dr. Holler has served as one of our directors since December 2005. Dr. Holler was one of the original founders of ID Biomedical Corporation in 1991 and was a member of its Board of Directors since inception. He held a number of executive positions with ID Biomedical, including Chief Executive Officer, until the company was acquired by GlaxoSmithKline in December 2005.

Prior to founding ID Biomedical, Dr. Holler served as an emergency physician at University Hospital at the University of British Columbia. He is a member of the British Columbia College of Physicians and Surgeons. Dr. Holler holds a Bachelor of Science degree and a medical degree from the University of British Columbia.

Member of: Audit Committee, Corporate Governance & Nominating Committee, Compensation Committee
David A. Johnson, MD, FACP, FACG, FASGE

David A. Johnson, MD, FACP, FACG, FASGE - Director

Dr. Johnson has been a director of the Company since June of 2010 and is a partner of Gastrointestinal and Liver Specialists of Tidewater PLLC in Norfolk, VA since 1989. Dr. Johnson was one of the founding members of CRH’s Scientific Advisory Board. He is Board-certified in Internal Medicine and Gastroenterology and is a past President, as well as a Master of the American College of Gastroenterology. Dr. Johnson currently serves as Professor of Medicine, Chief of Gastroenterology, in Eastern Virginia Medical School. He has authored more than 600 papers in the field of gastroenterology.
Todd Patrick

Todd Patrick - Director

Mr. Patrick is the President and Chief Executive Officer of C3J Therapeutics, Inc., a clinical stage biotechnology company based in Los Angeles, California. Prior to joining C3J, Mr. Patrick was the President and Chief Operating Officer of ID Biomedical Corporation. Mr. Patrick was with ID Biomedical from 1994 until 2005 when the company was acquired by GlaxoSmithKline. Prior to ID Biomedical, Mr. Patrick was the Director of the Office of Intellectual Property Administration at the University of California, Los Angeles (UCLA), where he was responsible for the patenting and licensing of intellectual property arising out of UCLA. Mr. Patrick holds a B.A. (Economics) from the University of Washington and a Master’s in Business Administration from Washington State University.
Mr. Patrick has been a director of the Company since May 2006.

Member of: Audit Committee, Corporate Governance & Nominating Committee, Compensation Committee
Ian Webb

Ian Webb - Director

Mr. Webb has been a director of the company since May 2006. He was admitted to the British Columbia bar in 1982 after graduating from Osgoode Hall Law School at York University with a Bachelor of Laws in 1981. Prior to that, Mr. Webb received a Master of Science in Theoretical Physics from the University of Saskatchewan in 1976.

Mr. Webb practiced in the areas of corporate and securities law with an emphasis on the legal requirements of public companies. He is a retired partner of the law firm Borden Ladner Gervais LLP.

Member of: Audit Committee, Corporate Governance & Nominating Committee, Compensation Committee
Edward Wright

Edward Wright - Chief Executive Officer, Director

Mr. Wright became CEO and director of the company in September of 2006. Prior to joining CRH he gained extensive management experience in global luxury brands at Richemont, the holding company for some of the world’s leading luxury goods. As President of Baume & Mercier first, and then as Executive Vice-President of North America Retail for Cartier, Mr. Wright developed an ability for building solid relationships with customers and business partners alike.

Upon arriving at CRH, Mr. Wright was tasked with maximizing the value of CRH’s O’Regan System. He quickly determined that CRH needed to transition from a retail model to a wholesale model and by introducing it to the gastrointestinal (“GI”) community in the US, he created a paradigm shift for gastrointestinal doctors (“GIs”) by extending their continuum of care for patients.

To maximize the value of CRH, Mr. Wright leveraged our relationships with the GI community leading to the launch of CRH Anesthesia Management, a business focused on providing GI anesthesia services to Ambulatory Surgical Centers (“ASCs”) across the US. CRH Anesthesia is now the primary driver of the company’s revenue and is positioned as one of the leading GI anesthesia brands in the US with outstanding growth potential.

Under Mr. Wright’s management CRH has become a profitable company with strong cash flow generation and access to North American capital markets to fund the company’s long-term growth strategy.

Mr. Wright is a member of the Young Presidents’ Organization and Chair of Vancouver College’s Board of Directors.
Back to topˆ
We're a stable, profitable company respected by both patients and physicians. Learn more »